Pure Financial Advisors’s GSK GSK Stock Holding History

Pure Financial Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$559K	Buy	10,662 +2,982	+39%	+$158K	0.01%	357
2026 Q1	$424K	Buy	7,680 +866	+13%	+$46.9K	0.01%	371
2025 Q4	$334K	Buy	6,814 +1,932	+40%	+$90.1K	﹤0.01%	399
2025 Q3	$211K	Buy	+4,882	New	+$191K	﹤0.01%	473

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Pure Financial Advisors's GSK Position: Q2 2026 in Review

Pure Financial Advisors increased its GSK (GSK) stake by 39% in Q2 2026, buying an estimated $158K and bringing the position to 10,662 shares worth $559K. The position accounts for 0.01% of the portfolio, ranked #357.

Pure Financial Advisors first reported a position in GSK in Q3 2025 and has held it in 4 quarters since. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Pure Financial Advisors held 10,662 shares of GSK worth $559K as of Q2 2026.
Pure Financial Advisors bought 2,982 GSK shares in Q2 2026, an estimated $158K.
GSK made up 0.01% of Pure Financial Advisors's portfolio in Q2 2026, its #357 holding.
Pure Financial Advisors first reported a position in GSK in Q3 2025 and has held it in 4 quarters since.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Pure Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.